Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 CPT code 84233

Estrogen receptor assay on tissue.

Follow the guidelines for CPT coding, particularly concerning laboratory tests and the reporting of multiple analytes, as outlined in the official CPT manual.

Modifiers 90 (Reference (Outside) Laboratory) and 91 (Repeat Clinical Diagnostic Laboratory Test) might be applicable depending on the circumstances.Other modifiers may apply based on the specific circumstances of service.

The medical necessity for an estrogen receptor assay is established when a patient presents with a breast tumor, or a suspected breast tumor, where determining the hormone receptor status is essential for tailoring cancer treatment. This includes initial diagnosis, treatment planning, monitoring for recurrence, and guiding decisions on adjuvant therapies.

The laboratory analyst is responsible for all technical aspects of the estrogen receptor assay, including sample preparation, ligand application, incubation, and measurement of radioactivity using a scintillation counter.

IMPORTANT:If immunohistochemical analysis is used instead of the described radioactively labeled ligand method, use an appropriate immunohistochemistry code instead of 84233.

In simple words: This lab test checks a tumor sample (usually from the breast) to see if it has estrogen receptors.The presence or absence of these receptors helps doctors decide on the best cancer treatment.

This code reports the performance of an estrogen receptor assay (ERA) on tissue, typically from a breast tumor.The assay analyzes for the presence of estrogen receptors, which are molecules that bind to the female hormone estrogen.The test involves freezing the tumor tissue, applying a radioactively labeled ligand that binds to estrogen receptors, incubating the sample, and measuring the radioactivity using a scintillation counter. The results are crucial in guiding treatment decisions for breast cancer, as ER-positive tumors (containing estrogen receptors) may respond differently to hormonal therapies compared to ER-negative tumors.

Example 1: A 55-year-old female patient presents with a breast mass. A biopsy is performed, and the tissue is sent to the lab for an estrogen receptor assay (84233). Results indicate ER-positive status, guiding the oncologist to prescribe hormonal therapy., A 48-year-old female patient with a history of breast cancer experiences recurrence. A new biopsy is analyzed using code 84233 to assess estrogen receptor status and determine if hormonal therapy should be continued or modified., A 60-year-old female patient undergoes a lumpectomy for breast cancer. The pathology report includes estrogen receptor status determined using code 84233, which informs the surgical team's decision on adjuvant therapies.

* Patient demographics and relevant medical history.* Detailed description of the tissue sample (source, type, quantity).* Date and time of sample collection and processing.* Detailed results of the estrogen receptor assay (quantitative or qualitative).* Physician's order specifying the test and the intended use of the results.

** The provided data is limited. For the most accurate and up-to-date information, please refer to the official CPT codebook and relevant payer guidelines.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.